Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome

European Journal of Immunology

Volumn 44, Issue 1, 2014, Pages 127-136

  Tadokera, Rebecca ^a   Meintjes, Graeme A ^a,b,c   Wilkinson, Katalin A ^a,d   Skolimowska, Keira H ^a,c   Walker, Naomi ^a,c   Friedland, Jon S ^c   Maartens, Gary ^a,e   Elkington, Paul T G ^c,f   Wilkinson, Robert J ^a,b,c,d  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b GF Jooste Hospital   (South Africa)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Drug therapy complications; HIV 1 infection; Immune reconstitution inflammatory syndrome; Matrix metalloproteinase; Tuberculosis

Indexed keywords

INTERSTITIAL COLLAGENASE; MATRILYSIN; PLACEBO; PREDNISONE; STROMELYSIN; STROMELYSIN 2; ANTIINFLAMMATORY AGENT; MATRIX METALLOPROTEINASE;

ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CELL CULTURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE DURATION; DRUG EFFECT; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION TUBERCULOSIS IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MYCOBACTERIUM TUBERCULOSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SYMPTOM; TISSUE INJURY; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; ADULT; AIDS RELATED COMPLEX; COMPLICATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; MALE; METABOLISM; MICROBIOLOGY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MONONUCLEAR CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CROSS-SECTIONAL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HIV-1; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOCYTES, MONONUCLEAR; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MYCOBACTERIUM TUBERCULOSIS; PREDNISONE; PROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84892455279     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343593     Document Type: Article

References (40)

1. Mocroft, A., Vella, S., Benfield, T. L., Chiesi, A., Miller, V., Gargalianos, P., d d'Arminio Monforte, A. et al., Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998. 352: 1725-1730.
2. Meintjes, G., Lawn, S. D., Scano, F., Maartens, G., French, M. A., Worodria, W., Elliott, J. H. et al., Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect. Dis. 2008. 8: 516-523.
3. Muller, M., Wandel, S., Colebunders, R., Attia, S., Furrer, H. and Egger, M., Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect. Dis. 2010. 10: 251-261.
4. Marais, S., Wilkinson, R. J., Pepper, D. J. and Meintjes, G., Management of patients with the immune reconstitution inflammatory syndrome. Curr. HIV/AIDS Rep. 2009. 6: 162-171.
5. Parks, W. C. and Shapiro, S. D., Matrix metalloproteinases in lung biology. Resp. Res. 2001. 2: 10-19.
6. Nagase, H. and Woessner, J. F., Jr., Matrix metalloproteinases. J. Biol. Chem. 1999. 274: 21491-21494.
7. Elkington, P. T., D'Armiento, J. M. and Friedland, J. S., Tuberculosis immunopathology: the neglected role of extracellular matrix destruction. Sci. Translat. Med. 2011. 3: 71-76.
8. Elkington, P. T., O'Kane, C. M. and Friedland, J. S., The paradox of matrix metalloproteinases in infectious disease. Clin. Exp. Immunol. 2005. 142: 12-20.
9. Sheen, P., O'Kane, C. M., Chaudhary, K., Tovar, M., Santillan, C., Sosa, J., Caviedes, L. et al., High MMP-9 activity characterises pleural tuberculosis correlating with granuloma formation. Eur. Respir. J. 2009. 33: 134-141.
10. Taylor, J. L., Hattle, J. M., Dreitz, S. A., Troudt, J. M., Izzo, L. S., Basaraba, R. J., Orme, I. M. et al., A role for matrix metalloproteinase-9 in granuloma formation during pulmonary Mycobacterium tuberculosis infection. Infect. Immun. 2006. 74: 6135-6144.
11. Gueders, M. M., Foidart, J. M., Noel, A. and Cataldo, D. D., Matrix metalloproteinases (MMPs) and tissue inhibitors of MMPs in the respiratory tract: potential implications in asthma and other lung diseases. Eur. J. Pharmacol. 2006. 533: 133-144.
12. Park, K. J., Hwang, S. C., Sheen, S. S., Oh, Y. J., Han, J. H. and Lee, K. B., Expression of matrix metalloproteinase-9 in pleural effusions of tuberculosis and lung cancer. Respiration 2005. 72: 166-175.
13. Shapiro, S. D., Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol. 1998. 10: 602-608.
14. Chang, J. C., Wysocki, A., Tchou-Wong, K. M., Moskowitz, N., Zhang, Y. and Rom, W. N., Effect of Mycobacterium tuberculosis and its components on macrophages and the release of matrix metalloproteinases. Thorax 1996. 51: 306-311.
15. Elkington, P., Shiomi, T., Breen, R., Nuttall, R. K., Ugarte-Gil, C. A., Walker, N. F., Saraiva, L. et al., MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J. Clin. Invest. 2011. 121: 1827-1833.
16. Elkington, P. T., Emerson, J. E., Lopez-Pascua, L. D., O'Kane, C. M., Horncastle, D. E., Boyle, J. J. and Friedland, J. S., Mycobacterium tuberculosis up-regulates matrix metalloproteinase-1 secretion from human airway epithelial cells via a p38 MAPK switch. J. Immunol. 2005. 175: 5333-5340.
17. Volkman, H. E., Pozos, T. C., Zheng, J., Davis, J. M., Rawls, J. F. and Ramakrishnan, L., Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010. 327: 466-469.
18. Tadokera, R., Meintjes, G., Skolimowska, K. H., Wilkinson, K. A., Matthews, K., Seldon, R., Chegou, N. N. et al., Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur. Resp. J. 2011. 37: 1248-1259.
19. Meintjes, G., Wilkinson, R. J., Morroni, C., Pepper, D. J., Rebe, K., Rangaka, M. X., Oni, T. et al., Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010. 24: 2381-2390.
20. Elkington, P. T. and Friedland, J. S., Matrix metalloproteinases in destructive pulmonary pathology. Thorax 2006. 61: 259-266.
21. Walker, N. F., Clark, S. O., Oni, T., Andreu, N., Tezera, L., Singh, S., Saraiva, L. et al., Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases. Am. J. Respir. Crit. Care Med. 2012. 185: 989-997.
22. Elkington, P. T., Nuttall, R. K., Boyle, J. J., O'Kane, C. M., Horncastle, D. E., Edwards, D. R. and Friedland, J. S., Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am. J. Respir. Crit. Care Med. 2005. 172: 1596-1604.
23. Green, J. A., Elkington, P. T., Pennington, C. J., Roncaroli, F., Dholakia, S., Moores, R. C., Bullen, A. et al., Mycobacterium tuberculosis upregulates microglial matrix metalloproteinase-1 and -3 expression and secretion via NF-kappaB- and activator protein-1-dependent monocyte networks. J. Immunol. 2010. 184: 6492-6503.
24. Friedland, J. S., Shaw, T. C., Price, N. M. and Dayer, J. M., Differential regulation of MMP-1/9 and TIMP-1 secretion in human monocytic cells in response to Mycobacterium tuberculosis. Matrix Biol. 2002. 21: 103-110.
25. Parks, W. C., Wilson, C. L. and Lopez-Boado, Y. S., Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 2004. 4: 617-629.
26. Wilson, C. L., Ouellette, A. J., Satchell, D. P., Ayabe, T., Lopez-Boado, Y. S., Stratman, J. L., Hultgren, S. J. et al., Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science 1999. 286: 113-117.
27. Li, Q., Park, P. W., Wilson, C. L. and Parks, W. C., Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell 2002. 111: 635-646.
28. Haro, H., Crawford, H. C., Fingleton, B., Shinomiya, K., Spengler, D. M. and Matrisian, L. M., Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J. Clin. Invest. 2000. 105: 143-150.
29. Manicone, A. M., Huizar, I. and McGuire, J. K., Matrilysin (matrix metalloproteinase-7) regulates anti-inflammatory and antifibrotic pulmonary dendritic cells that express CD103 (alpha(E)beta(7)-integrin). Am. J. Path. 2009. 175: 2319-2331.
30. Zuo, F., Kaminski, N., Eugui, E., Allard, J., Yakhini, Z., Ben-Dor, A., Lollini, L. et al., Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl. Acad. Sci. USA 2002. 99: 6292-6297.
31. Rosenberg, G. A., Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 2002. 8: 586-595.
32. Price, P., Mathiot, N., Krueger, R., Stone, S., Keane, N. M. and French, M. A., Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J. Clin. Virol. 2001. 22: 279-287.
33. Visse, R. and Nagase, H., Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003. 92: 827-839.
34. Mannello, F., Jung, K., Tonti, G. A. and Canestrari, F., Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. Clin. Biochem. 2008. 41: 1466-1473.
35. Jung, K., Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. Arterioscler. Thromb. Vasc. Biol. 2008. 28: e15-e16.
36. Murphy, G. and Nagase, H., Localizing matrix metalloproteinase activities in the pericellular environment. FEBS J. 2011. 278: 2-15.
37. Meintjes, G., Wilkinson, K. A., Rangaka, M. X., Skolimowska, K., van Veen, K., Abrahams, M., Seldon, R. et al., Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am. J. Respir. Crit. Care Med. 2008. 178: 1083-1089.
38. Haddow, L. J., Moosa, M. Y. and Easterbrook, P. J., Validation of a published case definition for tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010. 24: 103-108.
39. Eshun-Wilson, I., Havers, F., Nachega, J. B., Prozesky, H. W., Taljaard, J. J., Zeier, M. D., Cotton, M. et al., Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J. Int. Assoc. Phys. AIDS Care 2010. 9: 104-108.
40. Manosuthi, W., Van Tieu, H., Mankatitham, W., Lueangniyomkul, A., Ananworanich, J., Avihingsanon, A., Siangphoe, U. et al., Clinical case definition and manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2009. 23: 2467-2471.